ides Astellas with a top-tier oncology platform in the U.S. and an expanded product portfolio and pipelines. In addition to Tarceva®, we are pleased to add its oncology infrastructure, discovery platform, expanded pipelines and talent base to our existing businesses. We look forward to working together with our OSI colleagues to grow the combined business and realize our shared goal of improving the health of the people around the world every day."
Colin Goddard, Ph.D., Chief Executive Officer of OSI Pharmaceuticals, said, "We believe today's announcement recognizes the significant value we have built for our stockholders while providing the merged companies the opportunity to forge a stronger collective path forward in a shared mission to provide innovative new medicines to patients around the world."
Financial Details and Closing Conditions
This is an all-cash transaction with no financing conditions to close.
The transaction is subject to other customary closing conditions, including the tender of a majority of OSI's shares of common stock on a fully diluted basis. The HSR waiting period applicable to the acquisition of OSI by Astellas expired on March 19, 2010.
Astellas' all-cash tender offer for $57.50 per share for all of the currently outstanding shares of common stock (including the associated stock purchase rights) of OSI Pharmaceuticals, Inc. will expire no later than 10 business days after the amendment to the Schedule TO is filed (which is expected to be filed on or before May 21st), unless extended. As of 4:00 p.m. New York City time on Friday, May 14, 2010, 299,214 share
Page: 1 2 3 4 5 6 Related biology technology :1
|SOURCE Astellas Pharma US, Inc.; OSI Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC2
. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program3
. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case4
. CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection5
. Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)6
. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia7
. CV Therapeutics Statement on Unsolicited Proposal From Astellas8
. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal9
. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer10
. CV Therapeutics Board of Directors Rejects Astellas Tender Offer11
. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients